Both in Biotechnology
Replimune Group vs ADMA Biologics
Over the past year REPL returned +120.0% and ADMA returned −27.6%; their daily moves had a correlation of -0.08.
REPL +120.0% ADMA −27.6%Growth of $1, one year, split-adjusted
| Metric | REPL | ADMA |
|---|---|---|
| Price | $20.48 | $11.13 |
| Market cap | $1.94B | $2.49B |
| Today | −0.85% | +0.18% |
| 1 month | +54.5% | +9.3% |
| 6 months | +495.2% | +10.4% |
| Year to date | +110.6% | −39.0% |
| 1 year | — | −27.6% |
| Revenue growth (YoY) | — | +2.0% |
| Gross margin | — | 69.4% |
| Net margin | — | 30.4% |
| P/E (TTM) | — | 14.8× |
| Price / sales | — | 4.9× |
| Net cash | $183.7M | -$60.6M |
| Dividend yield | — | — |
| Volatility (60d) | 77.7% | 38.4% |
| Short % of float | 29.6% | 9.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).